BIBLIOGRAFÍA

1) Rosen CJ, Kesenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996; 51(4): 537-51.

2) Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD y col. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.

3) Fleisch H. Bisphosphonates: Pharmacology. Semin Arthritis Rheum 1994; 23: 261-2.

4) Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 93: 2004-11.

5) Fleisch H. Bisphosphonates in osteoporosis: An introduction. Osteoporos Int 1993; 3(Suppl): S3-5.

6) Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 6: 446-74.

7) Lin JH, Chen IW, Deluna FA, Hichens M. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Disp 1992; 20: 608-13.

8) Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Mineral Res 1993; 8: 199-208.

9) Stone M. Didronel PMO. Br J Hosp Med 1993; 49: 275-7.

10) Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 1994; 20: 717-34.

11) Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pharm 1994; 322: 1265-71.

12) Storm T, Thamsborg G, Steiniche T, Genant HK, Sörensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71.

13) Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD y col. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.

14) Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P. The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate. J Lab Clin Med 1971; 78: 574-84.

15) Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604.

16) Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on BMD in the hip and vertebrae: Four year randomized trial. Am J Med 1995; 99: 36-42.

17) Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH y col. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 33: 1437-43.

18) Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC y col. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 Dec 7; 348: 1535-41.

19) Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984; 2: 607.

20) Struys A, Sneler AA, Mulder H. Cyclic etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99: 235-40.

21) Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet 1988; (8578): 143-7.

22) Reid IR, Scholler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 1990; 5: 619.

23) Gallacher SJ, Fenner JA, Anderson K, Bryden FM, Banham SW, Logue FC y col. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47: 932-6.

24) Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S y col. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-9.

25) Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604.

26) Licata AA. From bathtub ring to osteoporosis. Cleve Clin J Med 1994; 60: 284-9.

27) Charhon S, Chapuy MC, Valentin-Opran A, Meunier PJ. Intravenous etidronate for spinal cord dysfunction due to Paget’s disease [carta]. Lancet 1982; (8268): 391-2.

28) Case Records of the Massachusetts General Hospital - Case 27461. N Engl J Med 1941; 225: 789-91.

29) Eto S. Hypercalcemia in malignancy. Rinsho-Byori 1994 Sep; 42(9): 943-51.

30) Ralston SH. Pathogenesis and management of cancer associated hypercalcemia. Cancer Surv 1994; 21: 179-96.

31) Tal A, Graves L. Intravenous pamidronate for hypercalcemia of primary hyper parathyroidism. South Med J 1996 ; 1989(6): 637-40.

32) Budayr AA, Zysset E, Jenzer A, Thiébaud D, Ammann P, Rizzoli R y col. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res 1994; 9 (4): 521-6.

33) ORourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994 May; 69(5): 914-7.

34) Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 1995; 6: 259-88.

35) Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339: 398-400

36) Goodman GA, Goodman LS. Las Bases Farmacológicas de la Terapéutica. Ed. Panamericana, 1986, 7ma. edición, Buenos Aires.

37) Liens D, Delmas PD, Meunir PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953-4.

38) Richardson AC, Tinling SP, Chole RA. Risedronate activity in the fetal and neonatal mouse. Otolaryngol Head Neck Surg 1993 Oct; 109(4): 623-33.

39) Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS y col. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-2.

40) Lombardi A, Santora AC. Clinical trials with bisphosphonates. Bone Miner 1993; 22(Suppl 1): S59.

41) Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D y col. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237-47.

42) Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates [carta]. Lancet 1983; 1(8322): 471.

43) Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP. Diphosphonates and inhibition of bone mineralization [carta]. Lancet 1982; 22(8298): 607-8.

44) Fleisch H. The Use of Bisphosphonates in Osteoporosis. Br J Clin Pharm 1994; 48: 323-6.

45) Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992; 26: 1262-9.

46) Roux C, Listrat V, Villette B, Lessana-Leibowitch M, Ethgen D, Pelissier C y col. Long-lasting dermatological lesions after tiludronate therapy. Calcif Tissue Int 1992; 50: 378-80.

Regresar